Six‐month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Aim : This study evaluated changes in clinical effectiveness measures of patients with type 2 diabetes initiating exenatide therapy in a real‐world setting. Methods : Eligible patients identified in the General Electric (GE) electronic medical record (EMR) research database from 1 January 2000 through 31 December 2007 were ≥18 years old with type 2 diabetes. Patients had prescription orders in the previous 395 days for metformin, a sulfonylurea, or a thiazolidinedione as monotherapy or in combination, and had at least 6 months of follow‐up activity. Baseline clinical measures were documented from 45 days prior up to 15 days after exenatide initiation and follow‐up measures documented at 6 months ± 45 days. Results : A total of 1709 patients were identified for study inclusion. The overall mean A1C reduction (s.e.m.) at 6 months was −0.8% (0.05) (p<0.001), weight loss was −3.2 kg (0.14) (p<0.001), blood pressure (BP) lowering was −1.9 mmHg (0.46) systolic blood pressure (SBP) (p<0.001) and −0.5 mmHg (0.27) diastolic blood pressure (DBP) (p = 0.078). Changes in low‐density lipoprotein (LDL), triglycerides and HDL were −7.4 mg/dl (1.7) (p<0.001), −23.2 mg/dl (6.7) (p = 0.001) and −0.8 mg/dl (0.33) (p = 0.012) respectively. In a quartile analysis by weight loss, mean A1C reduction ranged from −1.1 to −0.65% in the highest to lowest weight loss quartiles respectively. Conclusions : In a real‐world setting, exenatide initiation is associated with significant improvements in the measures of clinical effectiveness for type 2 diabetes. These reductions were comparable to those reported in randomized, controlled registration trials after 6 months of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522
Standards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055
The Look AHEAD Research Group (2003) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00064-3 · Cited by 767
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699
Self-citationBlonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00602.x · Cited by 416
Cited by
Glucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246
Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
“Furthermore, in small cohort studies conducted in type 2 diabetic patients, liraglutide and exenatide exhibited benefits in line with those seen in RCT on glycemic control, body weight, blood pressure, total cholesterol and triglycerides levels, and other known cardiovascular risk factors over a follow-up period of 36…”
BackgroundBuysschaert, M., Preumont, V., Oriot, P. R., Paris, I., Ponchon, M., Scarnière, D., & Selvais, P. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.03.009 · Cited by 68
Bergenstal, R. M., Li, Y., Porter, T. K. B., Weaver, C., & Han, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12026 · Cited by 31
Metadata
- Authors
- Brixner, D. I., McAdam‐Marx, C., Ye, X., Boye, K. S., Nielsen, L. L., Wintle, M., Misurski, D., & Fabunmi, R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2009-11-10
- Volume
- 11
- Issue
- 12
- Pages
- 1122-1130
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2150423648
- Cited by
- 38
- References
- 12
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Six‐month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. https://app.cochat.ai/papers/10.1111/j.1463-1326.2009.01081.x
- The paper
- Brixner, D. I., McAdam‐Marx, C., Ye, X., Boye, K. S., Nielsen, L. L., Wintle, M., Misurski, D., & Fabunmi, R. (2009). Six‐month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2009.01081.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.